Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction.
This retrospective observational intravascular ultrasound study evaluated whether simvastatin therapy limits lumen area reduction 1-year after percutaneous transluminal angioplasty (PTA) by reducing reactive plaque growth, reducing reactive vasoconstriction, or both. This study showed that plaque growth is a general response 1 year after PTA regardless of the use of simvastatin; simvastatin has the potential to induce positive vascular remodeling, thereby reducing the occurrence of restenosis.
Hagenaars
T
T
Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. hagenaars@tch.fgg.eur.nl
Gussenhoven
E J
EJ
van Sambeek
M R
MR
Jukema
J W
JW
Kranendonk
S E
SE
Bom
N
N
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011150:Popliteal Artery / Q000000981:diagnostic imaging / Q000473:pathology; D012189:Retrospective Studies; D019821:Simvastatin / Q000627:therapeutic use*; D018084:Ultrasonography, Interventional
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin